netFormulary NHS
Cambridgeshire and Peterborough
Formulary
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
Chapter Links...
 Details...
02.12  Expand sub section  Lipid-regulating drugs
02.12  Expand sub section  Statins
Atorvastatin
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Green

  • Primary prevention: 20mg daily.

  • Secondary prevention: 80mg daily.

 
Simvastatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
 
Link  MHRA: Simvastatin - updated advice on drug interactions
Link  MHRA: Simvastatin - dose limitations with concomitant amlodipine or diltiazem
Link  MHRA: Simvastatin - increased risk of myopathy at high dose (80 mg)
   
Pravastatin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green

  • First choice for HIV patients and transplant patients, low risk of interactions.

 
   
Rosuvastatin
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Green

  • Restricted to:

    • Patients without Familial Hypercholesterolaemia last line before the patient is considered for one of the PCSK9 inhibitors; alirocumab or evolocumab.

    • Patients with Familial Hypercholesterolemia second line to atorvastatin prescribed at the maximum tolerated dose (titrated to a 80mg).



 
   
02.12  Expand sub section  Bile acid sequestrants
02.12  Expand sub section  Ezetimibe
Ezetimibe
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Green

  • Recommended for treating primary heterozygous-familial and non-familial hypercholesterolaemia in line with NICE TA385

 
Link  NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
   
02.12  Expand sub section  Fibrates to top
Fenofibrate
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Green
 
Bezafibrate
View adult BNF View SPC online View childrens BNF  Track Changes
Second Choice
Green
 
   
02.12  Expand sub section  Nicotinic acid group
Nicotinic Acid
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital

  • CUHFT: Formulary

  • Non formulary at all other Trusts and in Primary Care

 
   
02.12  Expand sub section  Omega-3 fatty acid compounds
02.12  Expand sub section  PCSK9 inhibitors
Alirocumab
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital
High Cost Medicine
BlueTeq

  • Approved for treating primary hypercholesterolaemia and mixed dyslipidaemia in line with NICE TA393.

 
Link  NICE TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
   
Evolocumab
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red Hospital
High Cost Medicine
BlueTeq

  • Approved for treating primary hypercholesterolaemia and mixed dyslipidaemia in line with NICE TA394.

 
Link  NICE TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
   
02.12  Expand sub section  Other lipid modifying agents
 ....
 Non Formulary Items
Acipimox

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Grey
 
Atorvastatin and Ezetemibe  (Atozet)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black

  • Prescribe as individual constituents if required. Combination products are not recommended

 
Ciprofibrate

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Grey
 
Colesevelam  (Cholestagel)
(Tablets)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
  • Bile acid sequestrants are NOT RECOMMENDED for primary and secondary prevention of cardiovascular disease alone or in combination with a statin.
 
Colestipol  (Colestid)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
  • Bile acid sequestrants are NOT RECOMMENDED for primary and secondary prevention of cardiovascular disease alone or in combination with a statin.
 
Colestyramine  (Questran, Questran Light)
(Sachets (powder for oral suspension))

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
  • Bile acid sequestrants are NOT RECOMMENDED for primary and secondary prevention of cardiovascular disease alone or in combination with a statin.
 
Fluvastatin

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Grey
 
Gemfibrozil

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Grey
 
Lomitapide  (Lojuxta▼)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Grey
High Cost Medicine
 
Omega-3-Acid Ethyl Esters
(All brands including Omacor)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black

 




    • Not recommended for prescribing



 

Link  Items which should not routinely be prescribed in primary care
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

OTC

Available Over the Counter. Consider Self Care   

Green

Formulary - Can be prescribed in both secondary and primary care.   

Advice

Formulary - Specialist Advice, secondary care advice provided for primary care initiation.  

Amber No SCG

Formulary - Specialist initiation without shared care guidance.  

Amber SCG

Formulary - Specialist initiation with shared care guidance.  

Red Hospital

Restricted - Hospital only, not to be prescribed in primary care.  

Switch

Not recommended for prescribing. Switch to alternative cost-effective option.   

Black

Not recommended for prescribing in primary or secondary care.  

Grey

Not recommended as no formal application made for addition to the formulary. Contact relevant pharmacy team for further information.   

Non Formulary

Non-Formulary (category under review).  

netFormulary